Long Term Results Of Acurate Neo Transcatheter Valve
Jan Rychter1, Ali Aidibi2, Krystian Jakimowicz2, Roch Pakuła1, Tomasz Niklewski2, Michał Hawranek3, Mariusz Gąsior3, Michał Zembala2.
1Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Medical University of Silesia in Katowice, Silesian Centre for Heart Diseases, Zabrze, Poland, 2Department of Cardiac Surgery, Heart and Lung Transplantation and Mechanical Circulatory Support, Silesian Centre for Heart Diseases, Zabrze, Poland, 33rd Department of Cardiology, Medical University of Silesia in Katowice, Silesian Centre for Heart Diseases, Zabrze, Poland.
Background: Transcatheter aortic valve implantation (TAVI) has proven to be a valuable alternative to conventional surgical aortic valve replacement in patients who suffer from severe symptomatic aortic stenosis. Paravalvular leak (PVL), conduction disorders, and vascular complications still remain relevant procedure-related complications. The aim of this manuscript was to report our experience with ACURATE neo TF system.
Methods: From January 2014 until August 2020 one hundred ninety two (n = 192) patients with severe symptomatic aortic stenosis have been operated using the Acurate Neo Trans Femoral System. Patients were subject to in-hospital evaluation and one year follow-up.
Results: Mean patient age was 80 years; mean EUROscore II was 6.5%. The valve implantation procedure was safely and successfully performed in 99.1% of patients. Two patient needed conversion to aortic valve replacement. In 2.7% of patient vascular access site complication had occur. In-hospital mortality was 2.6%. At 5 year 3.7% of patients had died, 2.1% had disabling strokes, and 5.2% had permanent pacemaker implantations. Mean effective orifice area was 1.8 ± 0.3 cm2, mean gradient was 7 ± 3.1 mm Hg, and greater than mild paravalvular leakage was observed in 7.8% of patients.
Conclusions: Transfemoral implantation of the ACURATE neo prosthesis resulted in favorable 5-year clinical and echocardiographic outcomes with very low mortality and new pacemaker rates.
Back to 2022 Display Posters